Synergistic treatment of Huangqi injection and Danshen injection on serum inflammation in patients with stable coronary heart disease Effect of disease markers

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021590

Enrollment

Unknown

Registered

2019-02-28

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable coronary heart disease

Interventions

one:Standard treatment

two:Danshen injection treatment

three:Astragalus injection treatment

four:Danshen injection+Astragalus injection

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the SCAD diagnostic criteria; 2. The medical history is more than 3 months, and the frequency of angina pectoris is =3 times in the past 1 week, and the severity of angina pectoris is grade I~III; 3. Aged 18-75 years old; 4. SCAD patients were treated with any combination of cardiac-related drugs for more than 3 months prior to enrollment, including atorvastatin (20 mg qd), ASA, ACEIs, ARBs, and beta-blockers; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. With a condition of asymptomatic or stable symptoms after stable coronary artery syndrome (ACS); 2. Patients requiring revascularization, including myocardial infarction, left ventricular dysfunction, multivessel disease, and/or large-scale myocardial ischemia (ischemic area over 10%), left main disease, etc.; 3. Chronic refractory angina; 4. Combined with chronic kidney disease and severe heart, lung, liver and other important organ dysfunction; hematopoietic system and endocrine system and other serious primary diseases, malignant tumors, gastrointestinal bleeding, gastric ulcer and bleeding tendency are not expected unable to complete the study; 5. Severe and uncontrolled high blood pressure (SBP = 180 mmHg or DBP = 110 mmHg); 6. Severe arrhythmia (ventricular dichotomy, ventricular tachycardia, ventricular fibrillation, third degree atrioventricular block, arrest, severe sinus bradycardia, sick sinus syndrome, reentry supraventricular tachycardia, etc. Flow dynamics altered arrhythmia); 7. Participate in other clinical trials or take other proprietary Chinese medicines within 1 month; 8. Pregnancy or preparation for pregnancy, lactating women; 9. There are mental, psychological disorders and others who cannot cooperate with the completion of the research.

Design outcomes

Primary

Measure	Time frame
hs-CRP;WBC;IL-6;TNF-a;IL-1ß;IL-8;cTn;CK-MB;	—

Countries

China

Contacts

Public ContactYan Xia

Guangdong Provincial Hospital of Traditional Chinese Medicine

davidwang33@139.com+86 138262303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 28, 2026